Clinical application of daclizumab for prevention of acute renal allograft rejection

AIM: To investigate clinical application of daclizumab for prevention of acute rejection in renal transplant recipients. METHODS: This was a non randomized and retrospective study. A total of twenty eight renal transplant recipients(M 24,F 4; age 32 a± s 5 a) were studied and followed. A simultaneous cohort of eighty renal transplant recipients(M 68,F 12; age 34 a±11 a) served as control group. All of patients were addition of baseline regimen of mycophenolate mofetil(MMF), ciclosporin(CsA), methylprednisolone(MPD), and prednisone(Pred). The treatment of daclizumab was based on baseline regimen. The first dosage of daclizumab, 1 mg·kg -1 was administered by intraverous infusion over 15 min within 24 h prior to operation. The second same dosage was administered in the d 14 after operation. The rate of acute rejection, adverse reactions, infection episode, and patient and graft survival were observed. All of patients received a follow up of 12 mo at least. RESULTS: Acute rejection during the first 3 mo was significantly lower for daclizumb treated patients(4%) compared with control group(25%)( P 0.05). Daclizumab was well tolerated. There was no cytokine release syndrome related to daclizumab. No difference in infection episodes and adverse events between daclizumab group and control group. One year patient survival was 89% in daclizumab group, compared 96% in control group ( P 0.05), with graft survival of 89% and 94% for daclizumab and control group, respectively( P 0.05 ). CONCLUSION: The treatment consisting of daclizumab, MMF, CsA, MPD and Pred was effective in the prevention of acute rejection in renal transplant recipients.